The CSF2RB antibody targets the CSF2RB protein, a key component of the cytokine receptor family. CSF2RB, also known as interleukin-3 receptor subunit beta (IL3RB) or β common chain (βc), is a shared signaling subunit for receptors binding interleukin-3 (IL-3), interleukin-5 (IL-5), and granulocyte-macrophage colony-stimulating factor (GM-CSF). These cytokines regulate hematopoiesis, immune responses, and inflammation by activating downstream pathways like JAK/STAT, MAPK, and PI3K. The CSF2RB subunit is critical for receptor complex assembly and signal transduction. Mutations or dysregulation of CSF2RB are linked to hematopoietic disorders, autoimmune diseases, and certain cancers. Antibodies against CSF2RB are valuable tools for studying receptor expression, signaling mechanisms, and pathological roles in conditions like leukemia, asthma, or inflammatory syndromes. They are used in techniques such as Western blotting, flow cytometry, and immunohistochemistry to detect CSF2RB in research or diagnostic contexts. Additionally, therapeutic antibodies targeting CSF2RB or its associated pathways are under exploration to modulate immune responses or block aberrant signaling in malignancies. Understanding CSF2RB's role through antibody-based approaches aids in unraveling its contribution to both normal physiology and disease.